Intermediate hepatocellular carcinoma: new horizons and prospects for our patients.

IF 3.8 3区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Expert Review of Gastroenterology & Hepatology Pub Date : 2024-10-01 Epub Date: 2024-11-01 DOI:10.1080/17474124.2024.2422367

Federica Lo Prinzi, Federico Rossari, Marianna Silletta, Silvia Foti, Silvia Camera, Francesco Vitiello, Elisabeth Amadeo, Francesco De Cobelli, Luca Aldrighetti, Margherita Rimini, Andrea Casadei-Gardini

{"title":"Intermediate hepatocellular carcinoma: new horizons and prospects for our patients.","authors":"Federica Lo Prinzi, Federico Rossari, Marianna Silletta, Silvia Foti, Silvia Camera, Francesco Vitiello, Elisabeth Amadeo, Francesco De Cobelli, Luca Aldrighetti, Margherita Rimini, Andrea Casadei-Gardini","doi":"10.1080/17474124.2024.2422367","DOIUrl":null,"url":null,"abstract":"Introduction: In recent years, significant progress has been made in treatment strategies for intermediate-stage hepatocellular carcinoma (HCC), which is a highly heterogeneous patient population requiring tailored therapies based on tumor characteristics.Methods: We conducted a comprehensive review of treatment approaches for intermediate-stage HCC, highlighting the evolution of treatment options over time. While chemoembolization remains the standard therapy for many patients, it has advanced to include combinations with systemic therapies, known as combination therapy, which is becoming the new standard of care for this group.Conclusion: Based on our clinical and research experience, combination therapy is increasingly recognized as the preferred first-line treatment for intermediate-stage HCC patients. This approach allows most patients to be candidates for subsequent curative-intent treatments, while a smaller number will require palliative care.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"661-672"},"PeriodicalIF":3.8000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Gastroenterology & Hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17474124.2024.2422367","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/1 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: In recent years, significant progress has been made in treatment strategies for intermediate-stage hepatocellular carcinoma (HCC), which is a highly heterogeneous patient population requiring tailored therapies based on tumor characteristics.

Methods: We conducted a comprehensive review of treatment approaches for intermediate-stage HCC, highlighting the evolution of treatment options over time. While chemoembolization remains the standard therapy for many patients, it has advanced to include combinations with systemic therapies, known as combination therapy, which is becoming the new standard of care for this group.

Conclusion: Based on our clinical and research experience, combination therapy is increasingly recognized as the preferred first-line treatment for intermediate-stage HCC patients. This approach allows most patients to be candidates for subsequent curative-intent treatments, while a smaller number will require palliative care.

查看原文本刊更多论文

中期肝细胞癌：我们患者的新视野和新前景。

简介：近年来，中晚期肝细胞癌（HCC）的治疗策略取得了重大进展，中晚期肝细胞癌是一个高度异质性的患者群体，需要根据肿瘤特征采取定制疗法：我们对中晚期肝细胞癌的治疗方法进行了全面回顾，重点介绍了随着时间推移治疗方案的演变。虽然化疗栓塞仍是许多患者的标准疗法，但它已发展到与全身疗法相结合，即所谓的联合疗法，这正在成为这一群体的新治疗标准：根据我们的临床和研究经验，联合疗法越来越被认为是中晚期 HCC 患者的首选一线治疗方法。这种方法使大多数患者成为后续治疗的候选者，而少数患者则需要姑息治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Gastroenterology & Hepatology GASTROENTEROLOGY & HEPATOLOGY-

CiteScore

6.80

自引率

2.60%

发文量

审稿时长

6-12 weeks

期刊介绍： The enormous health and economic burden of gastrointestinal disease worldwide warrants a sharp focus on the etiology, epidemiology, prevention, diagnosis, treatment and development of new therapies. By the end of the last century we had seen enormous advances, both in technologies to visualize disease and in curative therapies in areas such as gastric ulcer, with the advent first of the H2-antagonists and then the proton pump inhibitors - clear examples of how advances in medicine can massively benefit the patient. Nevertheless, specialists face ongoing challenges from a wide array of diseases of diverse etiology.